HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Oct 15, 2013
Insider Transaction Report
Form 4
Kelly Michael P
President, NA, Global Plasma
Transactions
- Exercise/Conversion
Common Stock
2013-10-14$27.48/sh+1,400$38,479→ 12,737 total - Sale
Common Stock
2013-10-14$40.41/sh−1,400$56,568→ 11,337 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2013-10-14$40.41/sh−1,400$56,568→ 49,940 totalExercise: $27.48From: 2011-07-28Exp: 2017-07-28→ Common Stock (1,400 underlying)
Holdings
- 37,326
Non-Qualified Stock Option (right to buy)
Exercise: $30.67From: 2012-10-25Exp: 2018-10-25→ Common Stock (37,326 underlying) - 39,344
Non-Qualified Stock Option (right to buy)
Exercise: $39.05From: 2013-10-24Exp: 2019-10-24→ Common Stock (39,344 underlying) - 25,000
Performance Shares
Exercise: $0.00From: 2027-03-31Exp: 2027-12-31→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]Pursuant to a 10b5-1 Plan.
- [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F3]Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).